Review





Similar Products

pemetrexed  (MedChemExpress)
93
MedChemExpress pemetrexed
Pemetrexed, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pemetrexed/10__1016_slash_j__ijpx__2026__100558-58-0-4?v=MedChemExpress
Average 93 stars, based on 1 article reviews
pemetrexed - by Bioz Stars, 2026-07
93/100 stars
  Buy from Supplier
alimta  (Eli Lilly)
86
Eli Lilly alimta
Alimta, supplied by Eli Lilly, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pemetrexed/us12655159-436-11-12?v=Eli+Lilly
Average 86 stars, based on 1 article reviews
alimta - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier
mta  (Dentsply Sirona)
86
Dentsply Sirona mta
Mta, supplied by Dentsply Sirona, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pemetrexed/pmc13266017-66-38-41?v=Dentsply+Sirona
Average 86 stars, based on 1 article reviews
mta - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier
proroot mta  (Dentsply Sirona)
86
Dentsply Sirona proroot mta
Proroot Mta, supplied by Dentsply Sirona, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pemetrexed/pm42159272-165-4-6?v=Dentsply+Sirona
Average 86 stars, based on 1 article reviews
proroot mta - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier
pemetrexed  (Eli Lilly)
86
Eli Lilly pemetrexed
Overall Survival (OS) of patients with Leptomeningeal Metastasis (LM) from the whole cohort and Kaplan–Meier estimates based on clinical characteristics. A The median OS (mOS) of all the patients after diagnosis of LM was 8.0 months. B Patients with high Karnofsky Performance Status scores had better mOS (> 60 versus ≤ 60: 9.0 versus 5.0 months, hazard ratio [HR]: 0.60, P = 0.005). C Patients who had extensive systemic disease with few treatment options had slightly higher mOS (8.0 versus 6.0 months, HR: 0.65, P = 0.014). D Patients who received more than six times of intrathecal <t>pemetrexed</t> (IP) had better mOS (> 6 versus ≤ 6: 14.0 versus 5.0 months, HR: 0.41, P < 0.001). E Patients with response for IP treatment had better mOS (effective versus non-effective: 8.0 versus 4.0 months, HR: 0.50, P < 0.001). F Continued negative cerebrospinal fluid cytology after treatment was associated with longer survival (mOS 11.0 versus 5.0 months, HR: 0.42, P < 0.001)
Pemetrexed, supplied by Eli Lilly, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pemetrexed/pmc13192031-183-0-2?v=Eli+Lilly
Average 86 stars, based on 1 article reviews
pemetrexed - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier

Image Search Results


Overall Survival (OS) of patients with Leptomeningeal Metastasis (LM) from the whole cohort and Kaplan–Meier estimates based on clinical characteristics. A The median OS (mOS) of all the patients after diagnosis of LM was 8.0 months. B Patients with high Karnofsky Performance Status scores had better mOS (> 60 versus ≤ 60: 9.0 versus 5.0 months, hazard ratio [HR]: 0.60, P = 0.005). C Patients who had extensive systemic disease with few treatment options had slightly higher mOS (8.0 versus 6.0 months, HR: 0.65, P = 0.014). D Patients who received more than six times of intrathecal pemetrexed (IP) had better mOS (> 6 versus ≤ 6: 14.0 versus 5.0 months, HR: 0.41, P < 0.001). E Patients with response for IP treatment had better mOS (effective versus non-effective: 8.0 versus 4.0 months, HR: 0.50, P < 0.001). F Continued negative cerebrospinal fluid cytology after treatment was associated with longer survival (mOS 11.0 versus 5.0 months, HR: 0.42, P < 0.001)

Journal: BMC Cancer

Article Title: Real-world evidence for first-line intrathecal pemetrexed in leptomeningeal metastases from solid tumors: a retrospective cohort study

doi: 10.1186/s12885-026-15915-5

Figure Lengend Snippet: Overall Survival (OS) of patients with Leptomeningeal Metastasis (LM) from the whole cohort and Kaplan–Meier estimates based on clinical characteristics. A The median OS (mOS) of all the patients after diagnosis of LM was 8.0 months. B Patients with high Karnofsky Performance Status scores had better mOS (> 60 versus ≤ 60: 9.0 versus 5.0 months, hazard ratio [HR]: 0.60, P = 0.005). C Patients who had extensive systemic disease with few treatment options had slightly higher mOS (8.0 versus 6.0 months, HR: 0.65, P = 0.014). D Patients who received more than six times of intrathecal pemetrexed (IP) had better mOS (> 6 versus ≤ 6: 14.0 versus 5.0 months, HR: 0.41, P < 0.001). E Patients with response for IP treatment had better mOS (effective versus non-effective: 8.0 versus 4.0 months, HR: 0.50, P < 0.001). F Continued negative cerebrospinal fluid cytology after treatment was associated with longer survival (mOS 11.0 versus 5.0 months, HR: 0.42, P < 0.001)

Article Snippet: Pemetrexed (Alimta, Eli Lilly and Company, 100 mg) was dissolved in a 0.9% sodium chloride solution (3–5 mL) and prepared into a 50-mL mixture.

Techniques: Biomarker Discovery

The Overall Survival (OS) of patients with Leptomeningeal Metastasis (LM) from the Non-Small-Cell Lung Cancer (NSCLC) cohort and Kaplan–Meier estimates based on clinical characteristics. A The median OS (mOS) of all the patients after diagnosis of leptomeningeal metastasis (LM) was 6.0 months. B Patients with local treatment had better mOS (8.0 versus 3.0 months, hazard ratio [HR]: 0.58, P = 0.023). C Patients who received more than six times of intrathecal pemetrexed (IP) had better mOS (> 6 versus ≤ 6: 16.0 versus 4.0 months, HR: 0.33, P < 0.001). D Patients with response for IP treatment had better mOS (effective versus non-effective: 11.0 versus 3.5 months, HR: 0.46, P < 0.001). E Continued negative cerebrospinal fluid cytology after treatment was associated with longer survival (mOS 12.0 versus 4.0 months, HR: 0.41, P < 0.001)

Journal: BMC Cancer

Article Title: Real-world evidence for first-line intrathecal pemetrexed in leptomeningeal metastases from solid tumors: a retrospective cohort study

doi: 10.1186/s12885-026-15915-5

Figure Lengend Snippet: The Overall Survival (OS) of patients with Leptomeningeal Metastasis (LM) from the Non-Small-Cell Lung Cancer (NSCLC) cohort and Kaplan–Meier estimates based on clinical characteristics. A The median OS (mOS) of all the patients after diagnosis of leptomeningeal metastasis (LM) was 6.0 months. B Patients with local treatment had better mOS (8.0 versus 3.0 months, hazard ratio [HR]: 0.58, P = 0.023). C Patients who received more than six times of intrathecal pemetrexed (IP) had better mOS (> 6 versus ≤ 6: 16.0 versus 4.0 months, HR: 0.33, P < 0.001). D Patients with response for IP treatment had better mOS (effective versus non-effective: 11.0 versus 3.5 months, HR: 0.46, P < 0.001). E Continued negative cerebrospinal fluid cytology after treatment was associated with longer survival (mOS 12.0 versus 4.0 months, HR: 0.41, P < 0.001)

Article Snippet: Pemetrexed (Alimta, Eli Lilly and Company, 100 mg) was dissolved in a 0.9% sodium chloride solution (3–5 mL) and prepared into a 50-mL mixture.

Techniques: Biomarker Discovery